Paper Details

  1. Home
  2. Paper Details

ABT-737 and pictilisib synergistically enhance pitavastatin-induced apoptosis in ovarian cancer cells.

Author: De WolfChristopher, De WolfElizabeth, RichardsonAlan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Combining pitavastatin with either BH3 mimetics or pictilisib shows synergistic effects in killing ovarian cancer cells. This combination therapy may be effective in a subset of ovarian tumors, potentially reducing the dose required for pitavastatin and minimizing side effects.
Paper Details　
Original Abstract of the Article :
There is considerable interest in redeploying drugs for use in combination with other oncology therapeutics. The single-agent activity of statins in ovarian cancer has been widely reported, however the drug concentration required to cause cell death is considerably higher than that achieved in patie...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5778268/

データ提供：米国国立医学図書館（NLM）

ABT-737 and Pictilisib: New Paths to Combating Ovarian Cancer

Ovarian cancer is a challenging disease to treat. This research explores the potential of combining existing drugs to improve treatment outcomes. Imagine a camel seeking a new route through a desert, combining different paths to reach a desired destination. The researchers investigated the synergistic effects of combining ABT-737, a BH3 mimetic, and pictilisib, a phosphatidylinositol 3-kinase inhibitor, with pitavastatin, a statin, in ovarian cancer cells.

Combining Drugs for Improved Treatment Outcomes: A Synergistic Approach

The study found that combining ABT-737 or pictilisib with pitavastatin significantly enhanced cell death in ovarian cancer cells. It’s like combining different desert plants to create a more potent remedy – together, these drugs have a greater impact on the cancer cells.

New Hope for Ovarian Cancer Patients: A Beacon in the Desert

This research offers hope for new treatment approaches for ovarian cancer, suggesting that combining existing drugs might lead to improved efficacy and potentially reduce side effects. It's like finding a new oasis in the desert – this approach provides a potential solution to a challenging problem.

Dr. Camel's Conclusion

This research highlights the power of collaboration and innovation in the fight against ovarian cancer. It’s a reminder that we can often find better solutions by exploring new combinations and approaches, just like a wise camel seeking out new paths through a vast and challenging desert.

Date :
  1. Date Completed n.d.
  2. Date Revised 2020-10-01
Further Info :

Pubmed ID

29434898

DOI: Digital Object Identifier

PMC5778268

Related Literature

Article Analysis
・Side Effects of pitavastatin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.